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Abstract
Efavirenz is recommended as a preferred ﬁrst-line drug for women of childbearing potential living with human
immunodeﬁciency virus. Efavirenz is known for its central nervous system side effects, which are partly mediated by
serotonergic actions. The neurotransmitter serotonin exerts neurotrophic effects during neurodevelopment and
antenatal exposure to serotonergic agents has been linked to developmental delay. Although the teratogenic risks of
efavirenz appear to be minimal, data on long-term developmental effects remain scarce. Here, we aimed to investigate
the short- and long-term behavioral and neurodevelopmental effects of perinatal efavirenz exposure. We treated
pregnant rats from gestation day 1 until postnatal day 7 with efavirenz (100 mg/kg) or vehicle. We measured
behavioral outcomes in male offspring during the ﬁrst 3 postnatal weeks, adolescence and adulthood, and conducted
brain immunohistochemistry analyses after sacriﬁce. Perinatal efavirenz exposure resulted in reduced body weight and
delayed reﬂex and motor development. During adulthood, we observed a decrease in the total number of cells and
mature neurons in the motor cortex, as well as an increase in the number of Caspase-3-positive cells and serotonergic
ﬁbers. Together, our data show a developmental delay and persistent changes in the brain motor cortex of rats
exposed to efavirenz perinatally. Because over 1 million children born annually are exposed to antiretroviral therapy,
our ﬁndings underline the need for clinical studies on long-term neurodevelopmental outcomes of perinatal exposure
to efavirenz.
Introduction
Every year, an estimated 1.4 million women living with
human immunodeﬁciency virus (HIV) become pregnant.
The use of antiretroviral therapy (ART) during pregnancy,
delivery, and breastfeeding successfully reduces the risk of
mother-to-child transmission of HIV to <5%1. The latest
interim guidelines of the World Health Organization
(WHO) recommend dolutegravir as the general drug of
choice for people living with HIV2. However, due to
concerns about neural tube defects among ﬁrst-trimester
dolutegravir exposures, efavirenz (EFV) remains the pre-
ferred option in women of childbearing potential during
the periconception period3. Research on the safety of EFV
during pregnancy has focused largely on infant health
shortly after birth4. Although risks for gross teratogenicity
seem to be minimal, research on long-term neurodeve-
lopmental effects of perinatal exposure to EFV remains
scarce5,6.
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EFV passes through the placenta and is present in breast
milk, resulting in detectable concentrations in the blood
of fetuses and breast-fed infants7,8. After entry into the
blood stream, both EFV and its primary metabolite 8-
hydroxy-efavirenz (8-OH-EFV) readily penetrate the cer-
ebrospinal ﬂuid and target various cellular pathways
within the central nervous system (CNS), predominantly
the serotonergic system9–12. For example, EFV acts as a
serotonin(5-HT)6 receptor inverse agonist, 5-HT2A, 5-
HT2C, and 5-HT3A receptor antagonist, and a blocker of
the 5-HT transporter (5-HTT)13. In rats, EFV pre-
ferentially binds to the 5-HT2A receptor14.
Importantly, 5-HT exerts neurotrophic functions during
early development15,16. Increases in brain 5-HT levels,
induced by genetic 5-HTT inactivation, have been shown
to alter the serotonergic innervation of the prefrontal
cortex17, migration of inhibitory neurons to the neo-
cortex18, and maturation of the sensory cortex19. The
latter has also been observed after pharmacological 5-
HTT inhibition by prenatal selective serotonin reuptake
inhibitor (SSRI) exposure18,20. Both genetic and pharma-
cological 5-HTT modulation during early development
have been associated with a delay in reﬂex and motor
development, disturbed sensorimotor gating, decreased
social behavior, and anxiety and depression-like pheno-
types21–25. Moreover, children perinatally exposed to
SSRIs show reduced language and motor development,
and a twofold increased risk of autism spectrum pheno-
types26–28. Given that EFV particularly targets the ser-
otonergic system, we hypothesized that perinatal EFV
exposure might also lead to long-lasting neurodevelop-
mental consequences.
Here, we aimed to investigate the short- and long-term
behavioral and neurodevelopmental effects of perinatal EFV
exposure in a rodent model. We conducted a behavioral test
battery including tests for reﬂex development, motor per-
formance, sensorimotor gating and anxiety- and depressive-
like behavior, during early life, adolescence, and adulthood.
Throughout the treatment period, we monitored maternal
care. Because we observed changes in motor behavior, we
investigated the cytoarchitecture of the motor cortex to
study the underlying cellular mechanisms. Our results
indicate that perinatal EFV exposure is associated with
neurodevelopmental delay, accompanied by long-lasting
changes in motor cortex morphology.
Materials and methods
Animals
Rats used in this experiment were bred in-house from
Wistar male breeders and nulliparous Wistar females
weighing 185–215 g, purchased from Charles River,
Cologne, Germany. After a 2-week acclimatization period,
female rats were subjected to a timed mating procedure
(using Impedance Checker MK-10B, Muromachi Kikai,
Tokyo, Japan) as described previously25. Pregnancy was
determined by observation of a vaginal plug the day after
breeding gestational day (GD) 1. Pregnant rats were
alternately assigned to daily treatment with EFV or vehicle
from GD1 to postnatal day (PND) 7 by order of birth.
PND7 resembles the human functional brain maturity
around birth29. Litters were culled to 10 pups and pups
were weaned on PND21. One EFV-exposed pup died at
PND17 (cause unknown) and was excluded from analysis.
Male offspring from four EFV-exposed (n= 24) and four
vehicle-exposed nests (n= 20) were used for experiments.
Developmental milestones and behavior were assessed
during the ﬁrst 3 weeks of life (PND2–21), adolescence
(PND34–35), and adulthood (PND69–70). After com-
pletion of the last experiments, rats (PND73–75) were
sacriﬁced. Animal numbers used for each test are repor-
ted in the respective ﬁgure panels, where appropriate, and
in Supplementary Table 1.
Figure 1 shows a schematic representation of the
experimental timeline.
Sample sizes were based on power calculations from
previous studies using comparable animal models and
similar behavioral or molecular analyses23–25,30. Animals
were tested randomly and both investigators and care-
givers were blinded to the groups during experiments and
outcome assessment. Blinding was ensured using coded
treatment containers of identical appearance. Videos of
the reﬂex and motor performance tests were re-analyzed
by a second blinded researcher resulting in similar results.
Animals were housed in pairs in standard Macrolon® type
3 cages in temperature-controlled rooms (21 °C ± 1 °C)
under a standard 12-h light/dark cycle (lights on at
07:00 hours) with food and water available ad libitum (Sniff,
long cut pellet, Bio Services, Uden, The Netherlands).
Experiments were carried out in accordance with the Eur-
opean Communities Council Directive (2010/63/EU) and
approved by the Committee for Animal Experiments of the
Radboud university medical center Nijmegen, The Neth-
erlands (ref no. 2012-236).
Drug treatment
EFV or vehicle was administered blindly by oral gavage
in a volume of 5 mL/kg. We used a dose of 100mg/kg,
based on previous work demonstrating plasma levels
within the human therapeutic range (1.0–4.0 mg/L)31 and
unpublished pilot work. Drug solution was prepared by
diluting EFV oral suspension (Stocrin suspension 30mg/
mL, Merck Sharp & Dohme, Haarlem, The Netherlands)
with distilled water. As vehicle, we used a 1% cellulose
suspension (Genfarma B.V., Maarssen, The Netherlands),
enriched with the EFV solution additives, consisting of
medium chain triglyceride oil (Newpharma, Liège,
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Belgium) and strawberry and peppermint essence (Lecocq
N.V./S.A., Zonhoven, Belgium).
Measurement of EFV in blood plasma
Ninety minutes after drug administration at GD4, we
collected blood, obtained by tail cut, of all pregnant rats
(n= 8). Blood was collected in Microvette CB 300 tubes
(containing EDTA; Sarstedt, Germany) and centrifuged
for 15min at 4 °C with a speed of 4000 rpm. The super-
natant (plasma) was stored at −20 °C until analysis.
Supernatants from the experimental group were used for
determination of plasma peak EFV levels using a validated
reversed phase ultra-performance liquid chromatography
with ultraviolet detection bioanalytical assay, validated for
human plasma. For the current analysis, quality control
samples prepared with blank rat plasma were included to
assure validity of the assay. During the bioanalysis, the
quality control samples in rat plasma did not deviate more
than 15% from the theoretical value.
Maternal care
Maternal care was scored from PND2 to PND9 using a
procedure adapted from Ivy et al.32. Litters were observed
during three sessions per day of 75 min each: at 7:30 a.m.,
1:30 p.m. (light phase), and 7:30 p.m. (dark phase).
Throughout each session, behavior was scored every third
minute (25 observations per session). The behaviors
scored include: (1) nursing more than half of the nest, (2)
licking or grooming any pup, (3) spending time out of the
nest, (4) self-licking or grooming, and (5) eating or
drinking.
General development
Body weight was measured daily during early life
(PND2–21), adolescence (PND34), and adulthood
(PND70). In addition, we recorded eye opening every
morning from PND13 until both eyes were open. Scores
were deﬁned as: (0) both eyes closed, (1) one eye open, (2)
both eyes open. An eye was considered “open” if the
palpebral ﬁssure was ≥ 2 mm33.
Behavioral development
The experimental test battery was adapted from
Kroeze et al. and included the following functional
domains:25 reﬂex development (righting reﬂex, negative
geotaxis, and acoustic startle reﬂex), motor development
(swimming performance and bar holding), sensorimotor
gating (prepulse inhibition [PPI]), and anxiety- and
depressive-like behavior (elevated plus maze and forced
swim test).
Fig. 1 Experimental timeline. Pregnant dams were treated with efavirenz (EFV) (n= 4) or vehicle (n= 4) from GD1 until PND7. At GD4, plasma
levels of EFV were determined 1.5 h post administration. Developmental milestones and behavior were assessed during the ﬁrst 3 weeks of life
(PND2–21), adolescence (PND34–35), and adulthood (PND69–70). Maternal care was monitored from PND2 until PND9. After completion of the last
experiments, rats (PND73–75) were sacriﬁced and their brains were removed for immunohistochemistry analyses. GD gestational day, PND postnatal
day
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Reﬂex development—righting reﬂex, negative geotaxis,
acoustic startle reﬂex
During the righting reﬂex test, rats (PND2–10) were
placed on their back, while recording the time until they
returned to prostate position, with a maximum of 60 s34.
Negative geotaxis was examined using a 40° inclined
wooden plank with a wire mesh. Rats (PND4–14) were
placed facing down the slope and allowed to turn 180°
within 90 s21. All test sessions were recorded for later
rescoring by a second researcher. See below for methods
of the acoustic startle reﬂex.
Motor development—swimming performance, bar holding
During the swimming performance test, rats (PND8, 10,
12, 14, 22) were dropped from ± 20 cm into a basin ﬁlled
with 27 °C water and observed for 5–10 s. Scoring was
based on the position of the nose in the water: (1) entire
head underwater, (2) nose underwater, ears partially
underwater with the back of head above water level, (3)
nose above water level but ears partially underwater, (4)
entire head above water level35. Bar holding was tested by
positioning rats (PND10–21) with their forepaws on a
wooden bar (3 mm × 40 cm), suspended 45 cm above the
bench surface. The latency to fall from the bar was
recorded, with a maximum of 50 s. If the rat fell imme-
diately, the procedure was repeated up to three times25,36.
Acoustic startle reﬂex and sensorimotor gating—PPI
At PND21, 35, and 70, acoustic startle and PPI experi-
ments were performed in four acoustic startle chambers
(San Diego Instruments, San Diego, USA), according to
the methods of Sontag et al.37. Acoustic startle response
was deﬁned as the mean startle amplitude from the 10 test
blocks of the startle trials. The percentage of prepulse
inhibition was calculated using the formula: 100 – (aver-
age of startle amplitude on prepulse trial/average of startle
amplitude on startle trial) × 100%37.
Anxiety-like behavior—elevated plus maze
The elevated plus maze is a polyvinylchloride apparatus
with two open (50 × 10 cm, light intensity 12.1 lux) and
two enclosed (50 × 10 × 40 cm, light intensity 4.5 lux)
arms, elevated at a height of 50 cm38. Rats (PND69) were
placed in the center of the elevated plus maze facing one
of the open arms and allowed to freely explore the maze
for 5 min. Movements were measured using the EthoVi-
sion XT9 Tracking System, Noldus, Wageningen, The
Netherlands.
Depressive-like behavior—forced swim test
During the induction phase, rats (PND69) were placed
in cylindrical glass tanks (24 cm diameter × 65 cm height
ﬁlled to 35 cm with 22 °C water) for 15 min. After 24 h,
rats (PND70) were placed in the same tank for 5 min (test
phase). Immobility was deﬁned as no movements or
minimal movements necessary to keep the nose above
water level for ≥2 s. While slight movements of forepaws
or paw placement on cylinder walls were still considered
immobility, active climbing, diving, and swimming were
scored as mobility24. The duration of immobility (s) was
recorded with Observer XT 12.5 (Noldus Information
Technology, Wageningen, The Netherlands). Both phases
of the forced swim test (induction and test phase) were
performed at the end of the testing days (after completion
of the other behavioral tests).
Immunohistochemistry
After a minimum of 2 days after completion of the last
behavior experiments, rats (PND73–75) were deeply
anesthetized by an intraperitoneal injection of sodium
pentobarbital (200 mg/kg) and perfused transcardially
with cold phosphate-buffered saline (PBS), followed by 4%
paraformaldehyde (PFA). Brains were quickly removed
and immersed in 4% PFA for 48 h. Next, brains were
washed in PBS, placed in a 30% sucrose solution, frozen
on dry-ice, and stored at −80 C. In all, 16 μm sections
were cut on a Microm Cryostat, mounted on Superfrost®
Plus slides (Thermo Fisher Scientiﬁc, Waltham, MA,
USA), air-dried and stored desiccated at −20 °C. Cryo-
sections were obtained and stained immunohistochemi-
cally as previously described17, using the following
antibodies: mouse anti-NeuN (1:500, Merck Millipore,
Bedford, MA, USA; MAB377), rabbit anti-Cleaved Cas-
pase-3 (Casp3, 1:500, Cell Signaling Technologies, Dan-
vers, MA, USA; ASP175), rabbit anti-5-HT (1:500, Sigma-
Aldrich Chemie, Zwijndrecht, The Netherlands; S5545),
and rabbit anti-TH (1:500, Merck Millipore, Bedford, MA,
USA; AB152), species-speciﬁc Alexa-conjugated second-
ary antibody (1:500, Thermo Fisher Scientiﬁc; A32732).
After washing in PBS, sections were counterstained with
ﬂuorescent 2-(4-Amidinofenyl)-1H-indole-6-carbox-
amidine (DAPI,1:1000, Thermo Fisher Scientiﬁc; 62248)
diluted in PBS for 15 min, washed extensively in PBS and
embedded in 90% glycerol in PBS. For visualization, a
Leica DMRA ﬂuorescence microscope equipped with a
DFC340FX camera and LASAF software was used.
Quantiﬁcation
For quantiﬁcation of cells and ﬁbers in coronal sections,
pictures of at least ﬁve brains per group were acquired
similar to Witteveen et al.39. Stained cells were counted in
radial units of 0.1-mm wide in the presumptive primary
motor cortex (M1) of anatomically matched brain sec-
tions using Photoshop CS6 (Adobe). The overall cortical
length, above white matter, of M1 was divided into 10
equal bins (bin1 within the deep cortical layers and bin10
within the presumptive layer 1) within this rectangle,
ImageJ, including the NeuronJ plugin, was used for counts
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and measurements (National Institutes of Health,
Bethesda, USA).
Statistical analysis
Data are expressed as mean ± standard error of the
mean (SEM) unless indicated otherwise. Continuous
behavioral data were analyzed using repeated-measures
analysis of variance (ANOVA). In case of signiﬁcant vio-
lations of sphericity or error variances, the
Greenhouse–Geisser adjustment was applied and df were
adjusted. Signiﬁcant ANOVA results were followed by
post-hoc independent T-tests, in order to identify the
speciﬁc time points with the largest effect of EFV. Dif-
ferences in non-continuous data were analyzed by Pear-
son’s chi-square (or Fisher’s exact).
Immunohostochemical data were analyzed using one-way
ANOVA. We observed extreme outliers in the acoustic
startle/PPI test and removed these according to Tukey’s
principles. Cumulative behavioral development was
deﬁned using area-under-the-curves (AUC) for con-
tinuous data (righting reﬂex, negative geotaxis, bar hold-
ing) and sum scores for non-continuous data (swimming
performance). Spearman’s correlations were used to cor-
relate behavioral development with immunohistochem-
istry results. Statistical analyses were performed using
SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) and
GraphPad Prism3 software (California Corporation). All
tests were performed using a two-tailed hypothesis, with
signiﬁcance set at 0.05. The Benjamini–Hochberg proce-
dure was used for multiple comparisons behavioral post-
hoc analyses with a false discovery rate (FDR) of 0.1.
Results
Pregnancy outcomes and maternal care
On GD4, 1.5 h following the administration of EFV,
mean ( ± SEM) EFV plasma levels in EFV-treated dams
(n= 4) were 0.28 ± 0.13mg/l. Gestational length did not
differ between EFV (22.0 ± 0.0 days) and controls (22.3 ±
0.2 days, p= 0.69). No apparent anatomical abnormalities
were seen in the EFV-exposed offspring. Furthermore,
there were no signiﬁcant differences in the number of
pups per litter (EFV 10.8 ± 0.7 vs. controls 8.8 ± 1.3, p=
0.34), nor differences in the survival rates for pups at
weaning. Finally, the mean ( ± SEM) percentage of female
pups per litter did not differ between groups (EFV 42 ± 3%
vs. controls 41 ± 6%, p= 0.89; Supplemental Table S2). To
examine effects of EFV on dam–pup interactions, mater-
nal behavior was scored from PND2 until PND9 and did
not differ between groups (p > 0.10 for main effects of EFV
and interaction between time and EFV; Fig. 2a).
General development
Figure 2b shows the body weights of EFV- and vehicle-
exposed rats during early life (PND2–PND21),
adolescence (PND34), and adulthood (PND70). Body
weight increased with age (F(1.2, 49.3)= 6209.51, p <
0.0001). Perinatal EFV exposure was associated with
reduced weight gain (main effect EFV: F(1, 41)= 29.09, p <
0.0001; time × EFV interaction effect: F(1.2 ,49.3)= 7.99, p
= 0.0045). Body weight was signiﬁcantly reduced in EFV-
exposed rats for all testing days (post-hoc FDR-adjusted
p-values ≤ 0.0052). Eye opening was scored daily from
PND13–PND18. On PND17, EFV-exposed rats showed a
delay in eye opening (FDR-adjusted p= 0.0027, Fisher’s
exact; Fig. 2c).
Reﬂex and motor development
The time until the rats were able to roll from back to the
front (righting reﬂex) reduced with age (F(3.8, 158.4)= 20.09,
p < 0.0001; Fig. 2d). There were no main or interaction
effects of EFV on righting time. In the negative geotaxis test,
the time until turning decreased with age (F(5.0, 207.6)=
127.04, p < 0.0001; Fig. 2e). Rats perinatally exposed to EFV
showed a developmental delay for negative geotaxis (main
effect F(1, 41)= 13.59, p= 0.00066; time × EFV interaction
F(5.1, 207.6)= 0.1.17, p= 0.32). Post-hoc analyses showed
longer turning times in EFV-exposed animals on PND11
and PND12 (post-hoc FDR-adjusted p-values for both days
p= 0.075). We observed an improvement of performance
in the bar holding test over time (F(7.5, 306.6)= 35.02, p <
0.0001; Fig. 2f). We did not see any main effect of EFV on
bar holding (F(1, 41)= 1.17, p= 0.29), but we observed a
trend in time × EFV interaction (F(7.5, 306.6)= 1.81, p=
0.079), with signiﬁcant differences between groups on
PND20 (post-hoc FDR-adjusted p= 0.0048). In the swim-
ming test, EFV-exposed rats scored signiﬁcantly lower than
their controls on PND14 (FDR-adjusted p= 0.00046, Fish-
er’s exact; Fig. 2g). Finally, startle reﬂexes were assessed.
The amplitudes of the startle response increased over time
(F(1.5, 57.1)= 33.32, p < 0.0001; Fig. 3a), with a main effect of
EFV (F(1, 37)= 5.65, p= 0.023), and a trend for time × EFV
interaction (F(1.5, 57.1)= 2.72, p= 0.087). Post-hoc analyses
showed signiﬁcantly lower startle responses in the EFV
group in early life (PND21, post-hoc FDR-adjusted p=
0.049) and adolescence (PND35, post-hoc FDR-adjusted p
= 0.049), but not in adulthood (PND70, post-hoc FDR-
adjusted p= 0.95). Taken together, these data demonstrate
that EFV exposure affected early reﬂex and motor devel-
opment, which normalized in later life.
Development of sensorimotor gating and anxiety- and
depressive-like behavior
For all prepulses, the effects of PPI increased over time
(F(1.7, 56.3)= 36.76, p < 0.0001 for 3 dB, F(2, 70)= 33.21, p <
0.0001 for 5 dB, and F(1.18, 42.4)= 8.57, p= 0.0037 for
10 dB). We did not observe any main or interaction effects
of EFV on PPI, regardless of the prepulse strength (Fig.
3b–d). We found no group differences in elevated plus
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maze open arm time (F(1, 41)= 0.01, p= 0.92; Fig. 3e). The
number of open arm entries (F(1, 41)= 0.11, p= 0.74) and
closed arm entries (F(1, 41)= 0.01, p= 0.92) also did not
differ between control- and EFV-exposed rats (Fig. 3f, g),
suggesting that EFV did not affect anxiety. Finally, no
differences were found in the total distance moved (F(1, 41)
= 0.86, p= 0.361; Fig. 3h), indicating that EFV had also no
effect on exploratory locomotion. Due to video recording
errors, swimming scores could not be determined for two
EFV-exposed rats. While there were no differences
between the groups in the total duration of immobility
(F(1, 39)= 0.64, p= 0.48), or the total number of immobi-
lity counts (F(1, 39)= 0.598, p= 0.44), there was a sig-
niﬁcant difference in latency to the ﬁrst episode of
immobility (F(1, 39)= 9.88, p= 0.003), with EFV-exposed
rats exhibiting reduced latencies (Fig. 3i–k).
Motor cortex cytoarchitecture
To investigate whether perinatal EFV exposure affected
the architecture of the primary motor cortex (M1), we
assessed the M1 cell composition in randomly selected
brains from adult animals (PND73–75; Fig. 4a). We
observed a reduction in the total number of DAPI+ cells
in the M1 of the EFV-exposed compared with the control
group (p= 0.045; Fig. 4a–c and Supplemental Figure S1b).
This decrease was present in the superﬁcial layers (bin8,
p= 0.014; bin9, p= 0.00030) and to a lesser extent in
deep layers (bin6, p= 0.0096). Groups did not differ,
Fig. 2 Perinatal exposure to EFV signiﬁcantly affects body weight, eye opening, reﬂex and motor development, without effects on
maternal care. a No effect of EFV on maternal behaviors. (n= 4 litters per group, PND2–9). b, c Effects of perinatal EFV on general development. b
Main effect of EFV on body weight, with EFV-exposed rats showing reduced body weight. c EFV affects eye opening (PND17) scored as (0) both eyes
closed; (1) one eye open; (2) two eyes open (d, e). Effect of perinatal EFV on reﬂex development. d No effect of EFV on righting time (s) in the righting
reﬂex test. e Main effect of EFV on negative geotaxis test, with EFV-exposed rats exhibiting longer latencies (s) until turning 180°. f, g Effects of
perinatal EFV on motor development. f No main effect of EFV on the latency (s) to fall off the bar in the bar holding test, with a trend in EFV × time
interaction. g EFV affects swimming performance (PND14), scored as (1) entire head underwater, (2) nose underwater, ears partially underwater with
the back of head above water level, (3) nose above water, ears partially underwater, (4) entire head above water (PND8, 10, 12, 14, 22). EFV n= 24, Ctrl
n= 19. Data represent mean ( ± SEM), #p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed using repeated-measures ANOVA (a, b, d, e, f) or Fisher’s
exact (c, g). Ctrl vehicle, EFV efavirenz, PND postnatal day, N nursing, LG licking/grooming, C contact, X out of nest, SG self-grooming, ED eating/
drinking, ANOVA analysis of variance
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however, in M1 cortical thickness (p= 0.37; Supplemental
Figure S1g). To assess whether the observed reduction in
cells was neuron speciﬁc, we immunostained the M1 for
the neuronal nuclei marker NeuN (Fig. 4a, d, e). We found
a signiﬁcant reduction of NeuN+ neurons in the M1 of
the EFV-exposed group (p < 0.0001; Fig. 4d and Supple-
mental Figure S1c), which was present in all layers
(bin1–bin9, p < 0.05; Fig. 4e). Next, we focused on cell
apoptotic features of perinatal EFV exposure in the M1
(Fig. 4a, f, g). We observed a signiﬁcant increase of
Casp3+ cells in the M1 of EFV-exposed animals (p=
0.023; Fig. 4f and Supplemental Figure S1d), which was
apparent in deep (bin1, p= 0.0087; bin3, p= 0.0059; bin5,
p= 0.049 and bin6, p= 0.0071) and superﬁcial layers of
the M1 (bin7, p= 0.023 and bin9, p= 0.041; Fig. 4g) of
the M1. The number of NeuN+ neurons positive for
Casp3 was higher in the EFV-exposed group compared
with the control group (p= 0.037; Fig. 4h, i and Supple-
mental Figure S1e,f). In addition, we noticed a
small population of Casp3+ cells that were astrocytes
(positive for GFAP) (Supplemental Figure S1a). When
comparing nuclear size (using NeuN), we observed sig-
niﬁcantly reduced nuclear sizes in superﬁcial layers of the
EFV-exposed group (bin8, p= 0.0054; bin9, p= 0.0080;
Fig. 4j, k), suggesting a possible difference in apoptotic
state. Together, these data suggest (neuronal) cell loss in
M1 cortical areas, which persists into adulthood in peri-
natally EFV-exposed animals.
Given the serotonergic pharmacological proﬁle of EFV,
we hypothesized that early EFV exposure could have long-
term effects on the serotonergic system and potentially
indirectly on other neurotransmitter systems such as the
catecholaminergic system30. To test this hypothesis,
we immunostained M1 cortical slices for 5-HT and TH
(Fig. 5a, b) and found that perinatal EFV exposure was
associated with increased 5-HT+ ﬁber length (p= 0.028;
Fig. 5c, e) in deep and superﬁcial layers of the M1 (bin2, p
= 0.034; bin6, p= 0.040; Fig. 5c). We found no differences
in TH+ ﬁber length (p= 0.19; Fig. 5d, e), suggesting that
perinatal exposure to EFV inﬂuences the development
and maintenance of the serotonergic, but not the cate-
cholaminergic, system.
Fig. 3 Perinatal EFV exposure affects the startle reﬂex and latency to immobility in the forced swim test, but has no effects on prepulse
inhibition, or anxiety- and depressive-like behavior. a–d Effect of perinatal EFV on acoustic startle reﬂexes and prepulse inhibition (PPI). a Main
effect of EFV on average startle amplitude development, with EFV-exposed rats exhibiting shorter startle amplitudes. No effect of EFV on PPI on b
PND21, c PND35, and d PND70. PPI was calculated as: 100–(average of all startle amplitudes on prepulse trial/startle amplitude on startle trial) × 100%.
Three different prepulses were tested: 3 dB (PP3), 5 dB (PP5) or 10 dB (PP10) above background noise. e–h No effect of perinatal EFV on anxiety-like
behavior in the elevated plus maze. e Number of open arm entries, f number of closed arm entries, g time (s) spent in open arms, and h total
distance (cm) moved. i–k Effects of perinatal EFV on depressive-like behavior in the forced swim test. i No effect of EFV on the time (s) spent
immobile, or j the number of immobility times. k Main effect of EFV on the latency (s) to immobility, with EFV-exposed rats exhibiting shorter
latencies. EFV n= 24 (n= 22 for the forced swim test) and Ctrl n= 19. Data represent mean ( ± SEM), *p < 0.05, **p < 0.01, analyzed using repeated-
measures ANOVA (a–d) or one-way ANOVA (e–k). Ctrl vehicle, EFV efavirenz, PND postnatal day, PP prepulse, ANOVA analysis of variance
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Correlations between reﬂex and motor development and
M1 cytoarchitecture
Swimming performance correlated positively with the
number of cells (DAPI+; rs= 0.631, p= 0.009, Supple-
mental Figure S2) and post-mitotic neurons (NeuN+; rs=
0.642, p= 0.007) in the M1. In addition, we found a sig-
niﬁcant positive correlation between negative geotaxis
and 5-HT+ ﬁber length (rs= 0.700, p= 0.036) and a trend
between negative geotaxis and the number of DAPI+ cells
in M1 (rs=−0.492, p= 0.053). These results suggest that
Fig. 4 Perinatal exposure of EFV increases apoptosis in neurons of the motor cortex (M1). a Immunostaining for DAPI, mature neurons
(NeuN) and apoptosis (Caspase-3; Casp3) in the primary motor cortex (M1) of EFV-exposed (n= 8) and Ctrl-exposed (n= 8) animals. The boxed areas
are enlarged in (j). b, c Signiﬁcant decrease of the total number of DAPI+ cells in the superﬁcial cortical layer of the EFV-exposed group. d, e
Quantiﬁcation of mature neurons (Neun+) showing a signiﬁcant decrease in Neun+ cells in deep and superﬁcial layers in the EFV-exposed group. f, g
Quantitative results showing a signiﬁcant increase in Casp3+ cells in deep and superﬁcial layers of the M1 of EFV-exposed animals. h, i A signiﬁcant
increase in Casp3+/Neun+ cells in the EFV group compared with controls. k Signiﬁcant differences in the area occupied by Neun+ nuclei in two bins
of superﬁcial layers between EFV-treated and control animals. Data show mean ( ± SEM) number of cells, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed
using one-way ANOVA. Ctrl vehicle, EFV efavirenz, ANOVA analysis of variance
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the M1 of animals that performed better on the motor-
related tests contained more DAPI+ cells, more neurons
and shorter 5-HT ﬁbers.
Discussion
In this study, we demonstrate that perinatal exposure to
EFV in rats results in a transient delay in reﬂex and motor
development and in persistent changes in M1 cytoarchi-
tecture. Since maternal care was not affected by EFV
treatment, the behavioral changes most likely arise from
direct EFV brain toxicity. Correspondingly, EFV exposure
caused persistent structural changes in motor cortical
layers, reﬂected by a reduction in the number of mature
neurons. The increased number of Casp3+ neurons points
to neuronal cell death as the underlying cause. Finally, we
found increased serotonergic, but not catecholaminergic,
innervation of the M1 in EFV-exposed rats compared
with controls, indicating that EFV, either directly or
indirectly, affects the serotonergic system.
At the outset of our study, no studies had been pub-
lished on long-term neurodevelopmental effects of EFV.
Given EFV’ ability to interfere with the brain serotonergic
system12–14, we focused on behavioral domains known to
be affected by genetic or pharmacological inactivation of
the 5-HTT: reﬂex development22,40, motor perfor-
mance21,25, and emotion24,41. We found that perinatal
EFV exposure resulted in delayed reﬂex development,
reﬂected by increased latencies in the negative geotaxis
Fig. 5 Perinatal exposure to EFV affects serotonergic (but not catecholaminergic) innervation of the M1. a, b Camera lucida drawings of
immunostaining for a 5-HT+ and b TH+ ﬁbers in deep and superﬁcial layers of the M1 in EFV-exposed and Ctrl-exposed brains (n= 7 per group for
TH+ and n= 5 per group for 5-HT+). c Signiﬁcant increase in 5-HT+ ﬁber length in bin2 and 6 in the EFV group. d, e Signiﬁcant increase in 5-HT+ ﬁber
length, but no difference in TH+ ﬁber length in the total M1 area of the EFV-exposed group. Data show mean ( ± SEM) number of ﬁbers, *p < 0.05
analyzed using one-way ANOVA. 5-HT serotonin, Ctrl vehicle, EFV efavirenz, TH tyrosine hydroxylase, ANOVA analysis of variance
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test, and reduced startle responses. The reduced startle
responses may indicate decreased capability of these rats
to react to new auditory stimuli, but also point to a
reduced ability to initiate motor responses. Correspond-
ingly, EFV-exposed rats performed poorer in the swim-
ming and bar holding tests. Adequate swimming requires
the smooth integrative organization of multiple reﬂexes,
including vestibular reﬂexes and extensor-ﬂexor reﬂexes,
which progressively develop during the postnatal phase of
CNS maturation35. The delayed development of swim-
ming ability in EFV-exposed rats suggests that early EFV
exposure might modify these integrated neuromuscular
mechanisms. The fact that bar holding performance was
reduced, as well indicates that muscle strength may have
contributed to reduced swimming performance. We
observed no group differences in PPI, the elevated plus
maze test, or behavioral despair in the forced swim test.
We did, however, observe shorter latencies to immobility
in the forced swim test, possibly reﬂecting motor-related
problems. Taken together, these results suggest that
perinatal exposure to EFV affects reﬂex and motor
development, but not emotional behavior. The results are
in line with recent ﬁndings showing that, compared to
HIV-unexposed infants, HIV-uninfected infants perina-
tally exposed to EFV (aged 12–14 months) are at an
increased risk for motor delay (particularly those born
prematurely)6.
Alterations in care provided by the mother can poten-
tially mediate effects of EFV on motor development. As
one-third of EFV-treated adults report CNS symp-
toms10,42, and EFV-treated adult rats show anxiety and
depressive-like behavior14,43, dams treated with EFV may
have provided lower-quality care of pups than mothers
treated with vehicle. For this reason, we measured
maternal care and did not ﬁnd signiﬁcant differences
between EFV- and vehicle-treated dams. Hence, the
observed behavioral and morphological neurodevelop-
mental changes in EFV-exposed rats likely reﬂect (in)
direct drug toxicity, rather than indirect effects mediated
by altered maternal care.
To elucidate to what extent perinatal drug toxicity
effects could explain the observed delay in reﬂex- and
motor development, we investigated the cytoarchitecture
of the motor cortex (region M1) in adult rats. In the M1 of
perinatally EFV-exposed rats, we observed a marked
decrease in total cell numbers, including mature neurons,
and an increase in the number of neurons that expressed
the apoptotic marker Casp3. These ﬁndings indicate that
perinatal EFV causes cell death later in life, leading to a
partial loss of neurons. The positive correlation between
motor development and number of cells suggests that the
delayed motor function is related to reduced cell number
in the M1. The EFV-induced loss of cells may be attrib-
uted to EFV’ (in)direct ability to interfere with cellular
metabolism. For example, EFV has been shown to
decrease neuronal ATP storage, leading to increased
levels of reactive oxygen species and cell death44,45.
Alternatively, perinatal EFV exposure could indirectly
lead to neurodevelopmental changes and cell death, by
targeting the serotonergic system. We therefore deter-
mined whether the observed neuronal loss and cell death
were related to changes in the serotonergic system. We
measured the length of 5-HT+ and TH+ ﬁbers in the M1
and observed an increased length of 5-HT+, but not TH+,
ﬁbers, which correlated with reduced performance in the
negative geotaxis test. This result resembles the case of
perinatal SSRI exposure, which also results in increased
cortical serotonergic innervation in later life19,46. 5-HT is
one of the earliest neurotransmitter in the brain and
performs neurotrophic functions during early develop-
ment47. Hence, any interference with the serotonergic
system by perinatal drug exposure can have profound
long-lasting indirect effects on neurodevelopmental
events. The 5-HT2, 5-HT3, and 5-HT6 receptors are
involved in cell division48, differentiation49, survival50, and
neuronal migration pathways47. EFV, as a 5-HT receptor
(ant)agonist13, could directly interfere with these pro-
cesses, consequently leading to neuronal cell death45.
Elucidation of the exact molecular and cellular con-
sequences at various developmental time points after
perinatal EFV exposure in cortical and other brain areas
requires further research.
We observed no signs of EFV-related pregnancy com-
plications or teratogenicity, which is in line with ﬁndings
in a recent meta-analyses including 2026 ﬁrst-trimester
EFV exposures5. Still, EFV-exposed rats showed delayed
maturation (delayed eyelid opening) and reduced body
weights throughout life. Reduced birth weights have been
reported in EFV-exposed infants, although most studies in
humans report comparable birth weights with infants
exposed to other ART4,51,52. Interpretation of these data is
difﬁcult as drug-related effects cannot easily be isolated
from other HIV-related factors. Interestingly, the reduced
body weight ﬁnding is in line with animal and human data
derived from other early-life 5-HT stimulation mod-
els24,25,53. There are several ways in which EFV exposure
might reduce body weight: by 5-HT-dependent mechan-
isms, through interference with hypothalamic 5-HT
receptors and central regulation of eating behavior54, or
by 5-HT-independent mechanisms such as increased
metabolism and altered adipocyte differentiation55.
In contrast to other behavioral EFV studies14,43, we
measured plasma levels of EFV. Using a 100 mg/kg daily
dose, we produced EFV plasma levels that were detect-
able, yet below the therapeutic range in humans
(1.0–4.0 mg/L)56. One could argue that our experiment
was not representative for the human situation. However,
it is known that the main neurotoxic metabolite of EFV
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approximates human exposure, despite apparent relatively
low EFV plasma levels55, In addition, even at relatively low
concentrations, EFV has been shown to extensively
accumulate in brain tissue in rats57. Finally, at similar
doses in rats, EFV has been shown to induce neurotoxic
changes12. We, therefore, postulate that our experimental
set-up was sufﬁciently valid to induce the desired effects.
The major strength of using a rat model is that potential
HIV-related and socioeconomic confounders of adverse
neurodevelopmental effects of EFV in humans (e.g., par-
ental loss; co-medication) can be eliminated. As EFV did
not affect maternal care, developmental effects through
care provided by the mother can be excluded. Our study
also has limitations. We performed multiple behavioral
tests with the same animals, which could have inﬂuenced
test outcomes. We expect this carry-over effect to be
limited, as tests were generally not stressful. Furthermore,
behavioral and molecular experiments were performed
with the same animals. Motor behavior was measured
mostly during early life, while we only have molecular
data from adult rats. This makes it difﬁcult to draw
detailed mechanistic conclusions The signiﬁcant correla-
tions between adult M1 cortical architecture and early
motor performance, however, suggest that the M1 mole-
cular changes arise early during development and persist
throughout adulthood. Future studies using multiple time
points and, if possible, interventions, are needed to study
underlying mechanisms into more detail.
There is a clear indication of HIV treatment during
pregnancy as it not only protects the (unborn) child, but
also beneﬁts the mother’s health. The vast majority of
children exposed to EFV during pregnancy will be HIV
uninfected with normal life expectancies. However, this
outcome may come at a cost. As we demonstrate, peri-
natal exposure to EFV in rats leads to a transient delay in
reﬂex and motor development, and a long-lasting loss of
neurons in the motor cortex. Thus, EFV could affect the
development of children who may already be experiencing
multiple adverse conditions (such as having a mother
living with HIV). Our ﬁndings underline the need for
long-term clinical studies in children that are perinatally
exposed to EFV, as well as more detailed studies on the
underlying neurodevelopmental mechanisms.
Data deposition
Data used in this article are available from the corre-
sponding authors upon request.
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